

# EGETIS THERAPEUTICS

## PRESS RELEASE

Egetis Therapeutics AB  
Stockholm, Sweden, March 26, 2021

## Mats Blom nominated as new board member at Egetis Therapeutics

*Stockholm, Sweden, March 26, 2021. Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that the nomination committee proposes that Mats Blom is appointed Member of the Board of Directors of Egetis Therapeutics. Prof Sten Nilsson, who has served on the board since 2013, has declined reelection. The decision will be taken at the Annual General Meeting on April 29, and a notice will be sent out separately.*

Mats Blom has extensive managerial experience and has held CFO positions in several public and non-public companies, including 9 years at Zealand Pharma A/B, a biotechnology company dually listed on Nasdaq in New York and Copenhagen, and Swedish Orphan International. In addition, he has served as CFO at Modus Therapeutics, Active Biotech AB and Anoto Group AB.

Mats has also worked as a management consultant at Gemini Consulting and Ernst & Young. He holds a BA in Business Administration and Economics from the University of Lund and an MBA from IESE University of Navarra, Barcelona.

Mats is currently the CFO at NorthSea Therapeutics, a biotechnology company in the Netherlands, and board member of Hansa Biopharma and Auris Medical.

“We are incredibly happy to be able attract such a senior professional and executive as Mats to the board. Mats brings substantial experience within corporate governance, finance and the capital markets, establishing subsidiaries in the EU, and doing US listings on Nasdaq. He will definitely add valuable knowledge to Egetis when building an orphan late-stage development company for the future. Sten Nilsson, who has been with the company since 2013, has declined re-election, and I want to thank him for the skilled and invaluable work he has put into the business over this period”, said Kennet Rooth, Chairman of the nomination committee.

### For further information, please contact:

Nicklas Westerholm, CEO, Egetis Therapeutics  
Tel. +46 (0)73 354 20 62  
Email: [nicklas.westerholm@egetis.com](mailto:nicklas.westerholm@egetis.com)

*The information was submitted for publication, through the agency of the contact person set out above, at 2021-03-26,08:10 CET.*

# EGETIS THERAPEUTICS

## **About Egetis Therapeutics**

Egetis Therapeutics is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment. The drug candidate Emcitate is developed as the first potential treatment for patients with MCT8 deficiency, a rare disease with high unmet medical need and no available treatment. A Phase IIb clinical trial has been completed with significant and clinically relevant effects. A pivotal Phase IIb/III early intervention study has been initiated in Dec 2020 with the first patient dosed and interim results are expected in 2022. Emcitate holds Orphan Drug Designation in the US and EU and was granted Rare Pediatric Disease Designation by the US FDA in November 2020. The drug candidate Aladote is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for Aladote has been finalized after completed interactions with FDA, EMA and MHRA. Aladote has been granted Orphan Drug Designation in the US. Results from the PledOx POLAR program in Dec 2020 shows that PledOx did not meet the efficacy endpoint. Based on further evaluation of the results from the POLAR studies, the strategic next steps for PledOx will be determined together with our partner Solasia.

Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see [www.egetis.com](http://www.egetis.com)